Order Tests Now

EPISEEK® Multi-Cancer Early Detection

Invest in your patients’ health.

The Precision Epigenomics liquid biopsy test, EPISEEK, is a groundbreaking multi-cancer early detection (MCED) test that uses a simple blood draw to identify DNA changes associated with over 60 types of cancer. By detecting hypermethylated DNA loci—areas commonly hypermethylated across various cancers—EPISEEK enables early, accurate detection, even in individuals without prior signs of cancer.

Using advanced technology software, epigenomic modifications are analyzed. This technology is cost-effective, precise, and minimally invasive, and it may detect cancer earlier than imaging. It is also more accessible than a tissue biopsy.

Order Tests Now

The EPISEEK Test Detects All Major Cancer Types

Brain

Lung & Bronchus

Breast

Colon & Rectum

Prostate

Bladder

Kidney

Pancreas

Uterine and Cervical

Lymphoma

Myeloma & Leukemia

Thyroid

Oral

Liver

Esophagus

Ovarian

Skin

Feel in Control of Your Health

Talk to your healthcare professional about scheduling your EPISEEK multi-cancer early detection test.

%

5-Year Survival Rate

when cancer is detected early*

*The American Cancer Society

The Right Provider Is Committed to Keeping You Healthy

“As a physician, I know that early detection is critical in the fight against cancer. The EPISEEK liquid biopsy test is a groundbreaking tool that identifies cancer at its earliest stages, when it’s most treatable. I highly recommend Precision Epigenomics for its accuracy and its potential to save lives by catching cancer before symptoms begin. Not only do I order EPISEEK for my patients, but my healthcare provider also ordered it for me.”

 

– KRISTINE ROMINE, MD

More Than Just an Earlier Cancer Detection Test

It’s peace of mind.

Order Tests Now

Using a specificity of 99%, EPISEEK is predicted to have a positive predictive value (PPV) of 40% and a negative predictive value (NPV) of 99% in patients 50 years and older.

For aggressive stages I and II cancers that do not have widely adopted screening—such as bladder, esophagus, liver, head and neck SCC, lung, pancreas, stomach, and uterine—EPISEEK has a sensitivity of 57%. For stage III cancer, which is still operable in many cases, the sensitivity is 73%.